Canaan leaps into UK biotech by co-leading $14M Series A for immuno-oncology upstart Grey Wolf
Checkpoint inhibitors have done wonders for immuno-oncology, but the potent class of drugs doesn’t work across all cancers. To remedy this, UK-based biotech upstart Grey Wolf Therapeutics is working on a fresh approach that does not directly target the immune system, but instead alters tumor cells by illuminating and priming them for immune system annihilation — a strategy that could work in conjunction with existing immunotherapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.